PeptideInfo
Back to Directory

Semax

Phase II Trials

Also known as: Met-Glu-His-Phe-Pro-Gly-Pro

Educational Content Only

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.

Overview

Semax is a synthetic analogue of the ACTH 4-7 fragment, developed in Russia and studied for neuroprotective, nootropic, and neurotrophic effects. It is approved as a drug in Russia and Ukraine.

Possible Uses

The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.

  • Cognitive Enhancement
Mechanism of Action

Research indicates Semax may increase BDNF expression in the hippocampus, modulate dopamine and serotonin receptor systems, and exhibit antioxidant effects in neural tissue. It has been studied in the context of stroke recovery in animal models and clinical settings.

Safety Notes

Approved in Russia. Generally reported as well-tolerated. Limited long-term Western safety data.

Read More

Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.

Research Profile

Half-Life

~7 minutes (short; intranasal route studied)

Administration

intranasal, subcutaneous injection

Legal Status (US)

Research chemical in the US. Not FDA-approved.

162 indexed research passages

Categories
Cognitive & Neurological
Research Interest Areas
Cognitive Enhancement